These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2342974)

  • 1. Intraperitoneal alpha interferon for ovarian cancer: a case report.
    Carney-Gersten P; Moore MD; Giuffre M
    Oncol Nurs Forum; 1990; 17(3):403-7. PubMed ID: 2342974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
    Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
    Cancer Treat Rev; 1985 Dec; 12 Suppl B():23-32. PubMed ID: 3833327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
    Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of recombinant interferon alpha-2 (Sch 30500) in advanced gynecological cancers].
    Kasamatsu T; Ohmi K; Takeuchi S; Takamizawa H; Matsuzawa M; Kawana T; Ueda K; Kubo H; Tsumuji Y; Kawashima Y
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1656-60. PubMed ID: 3896157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma.
    Freedman RS; Gutterman JU; Wharton JT; Rutledge FN
    J Biol Response Mod; 1983; 2(2):133-8. PubMed ID: 6644331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant leukocyte alpha interferon in advanced ovarian carcinoma.
    Niloff JM; Knapp RC; Jones G; Schaetzl EM; Bast RC
    Cancer Treat Rep; 1985; 69(7-8):895-6. PubMed ID: 4016797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy: implications beyond ovarian cancer.
    Marin K; Oleszewski K; Muehlbauer P
    Clin J Oncol Nurs; 2007 Dec; 11(6):881-9. PubMed ID: 18063547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.
    Sarna GP; Figlin RA
    Cancer Treat Rep; 1985 May; 69(5):547-9. PubMed ID: 4005877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II studies of interferon alpha-2 Sch 30500 in advanced gastrointestinal carcinoma].
    Furue H
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1625-9. PubMed ID: 3896154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
    Vugrin D; Hood L; Laszlo J
    J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal chemotherapy for women with ovarian cancer: nursing care and considerations.
    Potter KL; Held-Warmkessel J
    Clin J Oncol Nurs; 2008 Apr; 12(2):265-71. PubMed ID: 18390462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
    Naumann RW; Sukumvanich P; Edwards RP
    Gynecol Oncol; 2009 Jul; 114(1):37-41. PubMed ID: 19410281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
    Rao G; Crispens M; Rothenberg ML
    J Clin Oncol; 2007 Jul; 25(20):2867-72. PubMed ID: 17617517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of weekly high-dose human lymphoblastoid interferon.
    Connors JM; Silver HK
    Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial.
    Sarna G; Figlin R; Callaghan M
    J Biol Response Mod; 1983; 2(4):343-7. PubMed ID: 6315898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
    Zeimet AG; Reimer D; Radl AC; Reinthaller A; Schauer C; Petru E; Concin N; Braun S; Marth C
    Anticancer Res; 2009 Jul; 29(7):2803-8. PubMed ID: 19596965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: a review of contributing factors.
    Anderson NJ; Hacker ED
    Clin J Oncol Nurs; 2008 Jun; 12(3):445-54. PubMed ID: 18515243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.